Do analysts prefer KZIA or CYPH?

Novogen currently has a consensus price target of $23.75, suggesting a potential upside of 67.12%. Given Novogen's stronger consensus rating and higher probable upside, research analysts plainly believe Novogen is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, KZIA or CYPH?

Cypherpunk Technologies has lower revenue, but higher earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 781.61 -$13.41M N/A N/A Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A

Is KZIA or CYPH more profitable?

Novogen's return on equity of 0.00% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Cypherpunk Technologies N/A -48.33% -42.21%

Which has preferable valuation & earnings, KZIA or CTOR?

Novogen has higher revenue and earnings than Citius Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 781.61 -$13.41M N/A N/A Citius Oncology N/A N/A -$24.76M -$0.47 N/A

Is KZIA or CTOR more profitable?

Novogen's return on equity of 0.00% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A Citius Oncology N/A -99.47% -42.16%

Which has better valuation & earnings, HYFT or KZIA?

Novogen has lower revenue, but higher earnings than MindWalk. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MindWalk $17.59M 4.26 -$21.69M -$0.20 N/A Novogen $30K 781.61 -$13.41M N/A N/A

Is HYFT or KZIA more profitable?

Novogen has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Novogen's return on equity of 0.00% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets MindWalk -66.79% -69.37% -39.74% Novogen N/A N/A N/A

Does the media favor HYFT or KZIA?

In the previous week, MindWalk had 3 more articles in the media than Novogen. MarketBeat recorded 6 mentions for MindWalk and 3 mentions for Novogen. Novogen's average media sentiment score of 0.96 beat MindWalk's score of 0.61 indicating that Novogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MindWalk 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer EXOZ or KZIA?

Novogen has a consensus target price of $23.75, indicating a potential upside of 67.12%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has better valuation & earnings, EXOZ or KZIA?

eXoZymes has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eXoZymes $70K 937.65 -$9.16M -$1.14 N/A Novogen $30K 781.61 -$13.41M N/A N/A

Is EXOZ or KZIA more profitable?

Novogen's return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Novogen N/A N/A N/A

Does the media refer more to EXOZ or KZIA?

In the previous week, Novogen had 1 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Novogen and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.98 beat Novogen's score of 0.96 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer KZIA or XBIT?

Novogen presently has a consensus target price of $23.75, indicating a potential upside of 67.12%. Given Novogen's stronger consensus rating and higher probable upside, research analysts clearly believe Novogen is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, KZIA or XBIT?

Novogen has higher revenue and earnings than XBiotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 781.61 -$13.41M N/A N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is KZIA or XBIT more profitable?

Novogen's return on equity of 0.00% beat XBiotech's return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A XBiotech N/A -26.10% -25.06%

Does the media prefer KZIA or XBIT?

In the previous week, Novogen and Novogen both had 3 articles in the media. XBiotech's average media sentiment score of 1.31 beat Novogen's score of 0.96 indicating that XBiotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Novogen (KZIA) Competitors

$14.21 -0.07 (-0.48%)

As of 10:33 AM Eastern

Compare

KZIA vs. CYPH, CTOR, HYFT, EXOZ, and XBIT

Should you buy Novogen stock or one of its competitors? MarketBeat compares Novogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novogen include Cypherpunk Technologies (CYPH), Citius Oncology (CTOR), MindWalk (HYFT), eXoZymes (EXOZ), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry.

How does Novogen compare to Cypherpunk Technologies?

Novogen (NASDAQ:KZIA) and Cypherpunk Technologies (NASDAQ:CYPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Novogen has a beta of 2.17, meaning that its stock price is 117% more volatile than the broader market. Comparatively, Cypherpunk Technologies has a beta of -0.02, meaning that its stock price is 102% less volatile than the broader market.

Cypherpunk Technologies has lower revenue, but higher earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	781.61	-$13.41M	N/A	N/A
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A

Novogen currently has a consensus price target of $23.75, suggesting a potential upside of 67.12%. Given Novogen's stronger consensus rating and higher probable upside, research analysts plainly believe Novogen is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.9% of Novogen shares are owned by institutional investors. Comparatively, 30.5% of Cypherpunk Technologies shares are owned by institutional investors. 1.0% of Novogen shares are owned by company insiders. Comparatively, 3.5% of Cypherpunk Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Novogen's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Cypherpunk Technologies	N/A	-48.33%	-42.21%

In the previous week, Novogen had 2 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 3 mentions for Novogen and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Novogen's score of 0.96 indicating that Cypherpunk Technologies is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Positive
Cypherpunk Technologies	Very Positive

Summary

Novogen beats Cypherpunk Technologies on 9 of the 12 factors compared between the two stocks.

How does Novogen compare to Citius Oncology?

Novogen (NASDAQ:KZIA) and Citius Oncology (NASDAQ:CTOR) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

30.9% of Novogen shares are held by institutional investors. Comparatively, 70.5% of Citius Oncology shares are held by institutional investors. 1.0% of Novogen shares are held by company insiders. Comparatively, 9.8% of Citius Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Novogen currently has a consensus price target of $23.75, suggesting a potential upside of 67.12%. Citius Oncology has a consensus price target of $6.00, suggesting a potential upside of 752.27%. Given Citius Oncology's higher probable upside, analysts plainly believe Citius Oncology is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Novogen has higher revenue and earnings than Citius Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	781.61	-$13.41M	N/A	N/A
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A

Novogen has a beta of 2.17, indicating that its share price is 117% more volatile than the broader market. Comparatively, Citius Oncology has a beta of 3.42, indicating that its share price is 242% more volatile than the broader market.

Novogen's return on equity of 0.00% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Citius Oncology	N/A	-99.47%	-42.16%

In the previous week, Novogen had 2 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Novogen and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.89 beat Novogen's score of 0.96 indicating that Citius Oncology is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Positive
Citius Oncology	Very Positive

Summary

Novogen beats Citius Oncology on 7 of the 12 factors compared between the two stocks.

How does Novogen compare to MindWalk?

MindWalk (NASDAQ:HYFT) and Novogen (NASDAQ:KZIA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Novogen has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Novogen's return on equity of 0.00% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Novogen	N/A	N/A	N/A

6.7% of MindWalk shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 1.0% of Novogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

MindWalk has a beta of 0.79, suggesting that its stock price is 21% less volatile than the broader market. Comparatively, Novogen has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market.

MindWalk presently has a consensus target price of $5.00, indicating a potential upside of 207.69%. Novogen has a consensus target price of $23.75, indicating a potential upside of 67.12%. Given MindWalk's higher possible upside, research analysts clearly believe MindWalk is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Novogen has lower revenue, but higher earnings than MindWalk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$17.59M	4.26	-$21.69M	-$0.20	N/A
Novogen	$30K	781.61	-$13.41M	N/A	N/A

In the previous week, MindWalk had 3 more articles in the media than Novogen. MarketBeat recorded 6 mentions for MindWalk and 3 mentions for Novogen. Novogen's average media sentiment score of 0.96 beat MindWalk's score of 0.61 indicating that Novogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Novogen beats MindWalk on 9 of the 14 factors compared between the two stocks.

How does Novogen compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, profitability, valuation and analyst recommendations.

eXoZymes has a beta of 2.66, suggesting that its stock price is 166% more volatile than the broader market. Comparatively, Novogen has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market.

In the previous week, Novogen had 1 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Novogen and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.98 beat Novogen's score of 0.96 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

eXoZymes has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	937.65	-$9.16M	-$1.14	N/A
Novogen	$30K	781.61	-$13.41M	N/A	N/A

Novogen's return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Novogen	N/A	N/A	N/A

Novogen has a consensus target price of $23.75, indicating a potential upside of 67.12%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

30.9% of Novogen shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 1.0% of Novogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Novogen beats eXoZymes on 7 of the 13 factors compared between the two stocks.

How does Novogen compare to XBiotech?

Novogen (NASDAQ:KZIA) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Novogen has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Novogen's return on equity of 0.00% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
XBiotech	N/A	-26.10%	-25.06%

Novogen presently has a consensus target price of $23.75, indicating a potential upside of 67.12%. Given Novogen's stronger consensus rating and higher probable upside, research analysts clearly believe Novogen is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.9% of Novogen shares are held by institutional investors. Comparatively, 55.7% of XBiotech shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 30.8% of XBiotech shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Novogen and Novogen both had 3 articles in the media. XBiotech's average media sentiment score of 1.31 beat Novogen's score of 0.96 indicating that XBiotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novogen has higher revenue and earnings than XBiotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	781.61	-$13.41M	N/A	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

Summary

Novogen beats XBiotech on 8 of the 11 factors compared between the two stocks.

Get Novogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZIA vs. The Competition

Export

Metric	Novogen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.46M	$3.39B	$6.49B	$12.31B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	N/A	20.05	24.05	24.76
Price / Sales	781.61	325.48	542.61	168.32
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-2.66	8.16	10.69	6.90
Net Income	-$13.41M	$23.89M	$3.57B	$337.45M
7 Day Performance	24.66%	3.66%	1.56%	2.84%
1 Month Performance	7.99%	1.69%	2.49%	4.78%
1 Year Performance	52.81%	46.95%	26.51%	33.08%

Novogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZIA Novogen	2.2233 of 5 stars	$14.21 -0.5%	$23.75 +67.1%	+53.5%	$23.46M	$30K	N/A	12
CYPH Cypherpunk Technologies	0.5916 of 5 stars	$0.68 -4.6%	N/A	+58.6%	$75.40M	N/A	N/A	40	Positive News Gap Up
CTOR Citius Oncology	1.9857 of 5 stars	$0.72 -10.0%	$6.00 +733.6%	-54.8%	$74.38M	N/A	N/A	N/A	Positive News
HYFT MindWalk	3.0651 of 5 stars	$1.66 +3.8%	$5.00 +201.2%	N/A	$73.85M	$17.59M	N/A	80
EXOZ eXoZymes	0.6135 of 5 stars	$7.80 -9.5%	N/A	-44.6%	$73.09M	$70K	N/A	29	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZIA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novogen (KZIA) Competitors

KZIA vs. CYPH, CTOR, HYFT, EXOZ, and XBIT

How does Novogen compare to Cypherpunk Technologies?

Summary

How does Novogen compare to Citius Oncology?

Summary

How does Novogen compare to MindWalk?

Summary

How does Novogen compare to eXoZymes?

Summary

How does Novogen compare to XBiotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novogen (KZIA) Competitors

KZIA vs. CYPH, CTOR, HYFT, EXOZ, and XBIT

How does Novogen compare to Cypherpunk Technologies?

Which has more risk and volatility, KZIA or CYPH?

Which has preferable earnings and valuation, KZIA or CYPH?

Do analysts prefer KZIA or CYPH?

Do institutionals and insiders hold more shares of KZIA or CYPH?

Is KZIA or CYPH more profitable?

Does the media favor KZIA or CYPH?

Summary

How does Novogen compare to Citius Oncology?

Do institutionals & insiders hold more shares of KZIA or CTOR?

Do analysts rate KZIA or CTOR?

Which has preferable valuation & earnings, KZIA or CTOR?

Which has more risk and volatility, KZIA or CTOR?

Is KZIA or CTOR more profitable?

Does the media prefer KZIA or CTOR?

Summary

How does Novogen compare to MindWalk?

Is HYFT or KZIA more profitable?

Do institutionals & insiders believe in HYFT or KZIA?

Which has more risk and volatility, HYFT or KZIA?

Do analysts recommend HYFT or KZIA?

Which has better valuation & earnings, HYFT or KZIA?

Does the media favor HYFT or KZIA?

Summary

How does Novogen compare to eXoZymes?

Which has more risk and volatility, EXOZ or KZIA?

Does the media refer more to EXOZ or KZIA?

Which has better valuation & earnings, EXOZ or KZIA?

Is EXOZ or KZIA more profitable?

Do analysts prefer EXOZ or KZIA?

Do insiders & institutionals believe in EXOZ or KZIA?

Summary

How does Novogen compare to XBiotech?

Which has more risk & volatility, KZIA or XBIT?

Is KZIA or XBIT more profitable?

Do analysts prefer KZIA or XBIT?

Do institutionals & insiders have more ownership in KZIA or XBIT?

Does the media prefer KZIA or XBIT?

Which has preferable valuation and earnings, KZIA or XBIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools